253 related articles for article (PubMed ID: 20203106)
1. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
3. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
Vethanayagam RR; Wang H; Gupta A; Zhang Y; Lewis F; Unadkat JD; Mao Q
Drug Metab Dispos; 2005 Jun; 33(6):697-705. PubMed ID: 15743976
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
7. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
9. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
Henriksen U; Gether U; Litman T
J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
[TBL] [Abstract][Full Text] [Related]
10. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.
Wang H; Lee EW; Cai X; Ni Z; Zhou L; Mao Q
Biochemistry; 2008 Dec; 47(52):13778-87. PubMed ID: 19063604
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
12. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
13. BCRP transports dipyridamole and is inhibited by calcium channel blockers.
Zhang Y; Gupta A; Wang H; Zhou L; Vethanayagam RR; Unadkat JD; Mao Q
Pharm Res; 2005 Dec; 22(12):2023-34. PubMed ID: 16247709
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
15. pH-Dependent transport of pemetrexed by breast cancer resistance protein.
Li L; Sham YY; Bikadi Z; Elmquist WF
Drug Metab Dispos; 2011 Sep; 39(9):1478-85. PubMed ID: 21628496
[TBL] [Abstract][Full Text] [Related]
16. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.
Han Y; Riwanto M; Go ML; Ee PL
Eur J Pharm Sci; 2008 Sep; 35(1-2):30-41. PubMed ID: 18598762
[TBL] [Abstract][Full Text] [Related]
17. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
18. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
19. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
20. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]